John Tesh is continuing to battle cancer ten years after doctors gave him 18 months to live. "I was given 18 months to live," the former TV personality told Page Six. "So, I’ve been fighting cancer ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...